Contrasting BetterLife Pharma (OTCMKTS:PVOTF) and Leap Therapeutics (NASDAQ:LPTX)

BetterLife Pharma (OTCMKTS:PVOTF) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Earnings & Valuation

This table compares BetterLife Pharma and Leap Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A
Leap Therapeutics	$1.50 million	49.49	-$81.41 million	($2.39)	-1.21

BetterLife Pharma has higher earnings, but lower revenue than Leap Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BetterLife Pharma and Leap Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BetterLife Pharma	0	0	0	0	N/A
Leap Therapeutics	0	0	5	0	3.00

Leap Therapeutics has a consensus price target of $10.40, indicating a potential upside of 258.62%.

Insider and Institutional Ownership

30.5% of Leap Therapeutics shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by company insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BetterLife Pharma and Leap Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BetterLife Pharma	N/A	-205.15%	-147.23%
Leap Therapeutics	N/A	-98.01%	-81.43%

Summary

Leap Therapeutics beats BetterLife Pharma on 5 of the 8 factors compared between the two stocks.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.